<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Amneal Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc</link>
<description>Latest news and press releases for Amneal Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 10:17:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/amneal-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7337651cc36e47532d8e1.webp</url>
<title>Amneal Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc</link>
</image>
<item>
<title>Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader</guid>
<pubDate>Wed, 22 Apr 2026 10:17:00 GMT</pubDate>
<description>PISCATAWAY, N.J., April 22, 2026--Kashiv BioSciences, LLC ("Kashiv"), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal"). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026.</description>
</item>
<item>
<title>Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance</guid>
<pubDate>Wed, 22 Apr 2026 10:00:00 GMT</pubDate>
<description>– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance – – Company to Host Investor Conference Call Today at 8:30 a.m. EST – BRIDGEWATER, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a diversified, global biopharmaceutical leader focused on expand</description>
</item>
<item>
<title>Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-additional-positive-interim-phase-4-elevate-pd-results-with-crexontr-for-parkinsons-disease-including-over-3-more-hours-of-daily-good-on-time-when-switching-from-rytaryr</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-additional-positive-interim-phase-4-elevate-pd-results-with-crexontr-for-parkinsons-disease-including-over-3-more-hours-of-daily-good-on-time-when-switching-from-rytaryr</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsDemonstrated substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function after switching to CREXONT®Patients switching to CREXONT® from RYTARY® gained 3.07 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted period</description>
</item>
<item>
<title>Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-launches-first-two-respiratory-metered-dose-inhalation-products-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-launches-first-two-respiratory-metered-dose-inhalation-products-in-the-us</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-launches-bimatoprost-ophthalmic-solution-001percent</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-launches-bimatoprost-ophthalmic-solution-001percent</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., April 09, 2026 (GLOBE</description>
</item>
<item>
<title>Amneal to Report First Quarter 2026 Results on May 1, 2026</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-report-first-quarter-2026-results-on-may-1-2026</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-report-first-quarter-2026-results-on-may-1-2026</guid>
<pubDate>Tue, 07 Apr 2026 20:01:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for</description>
</item>
<item>
<title>Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-dollar2-million-donation-to-support-patient-access-to-essential-medicines-during-parkinsons-awareness-month</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-dollar2-million-donation-to-support-patient-access-to-essential-medicines-during-parkinsons-awareness-month</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations</description>
</item>
<item>
<title>Amneal to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-participate-in-upcoming-investor-conference-66</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-participate-in-upcoming-investor-conference-66</guid>
<pubDate>Thu, 05 Mar 2026 21:05:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the following upcoming investor conference: Barclays 28th Annual Global Healthcare ConferenceDate: March 10, 2026Fireside Chat: Tuesday, March 10, 2026, at 11:00AM ESTLocation: Miami, FL A webcast of the presentation will be available on Amneal’s Investor Relations website at https://investors</description>
</item>
<item>
<title>Amneal Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net</description>
</item>
<item>
<title>Amneal Pharmaceuticals Added to S&P SmallCap 600® Index</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-pharmaceuticals-added-to-sandp-smallcap-600r-index</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-pharmaceuticals-added-to-sandp-smallcap-600r-index</guid>
<pubDate>Wed, 28 Jan 2026 21:05:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026. Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seekin</description>
</item>
<item>
<title>Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-report-fourth-quarter-and-full-year-2025-results-on-february-27-2026</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-report-fourth-quarter-and-full-year-2025-results-on-february-27-2026</guid>
<pubDate>Tue, 27 Jan 2026 13:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individua</description>
</item>
<item>
<title>Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-fda-approval-of-denosumab-biosimilars-referencing-proliar-and-xgevar</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-fda-approval-of-denosumab-biosimilars-referencing-proliar-and-xgevar</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22,</description>
</item>
<item>
<title>Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-approval-for-epinephrine-injection-in-single-and-multi-dose-vials-for-us-hospitals</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-approval-for-epinephrine-injection-in-single-and-multi-dose-vials-for-us-hospitals</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025</description>
</item>
<item>
<title>Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-positive-interim-phase-4-elevate-pd-results-with-crexontr-for-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-positive-interim-phase-4-elevate-pd-results-with-crexontr-for-parkinsons-disease</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions,</description>
</item>
<item>
<title>Amneal to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences: Piper Sandler 2025 Healthcare ConferenceDate: December 3, 2025Fireside Chat: Wednesday, December 3, 2025, at 9:30AM ESTLocation: New York, NY J.P. Morgan 2026 Healthcare ConferenceDate: January 12-15, 2026Presentation: Tuesday,</description>
</item>
<item>
<title>Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-approval-for-albuterol-sulfate-inhalation-aerosol</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-approval-for-albuterol-sulfate-inhalation-aerosol</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>Represents second complex respiratory therapeutic product approval in Q4 2025 BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals,</description>
</item>
<item>
<title>Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-us-fda-approval-of-cyclosporine-ophthalmic-emulsion-005percent</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-announces-us-fda-approval-of-cyclosporine-ophthalmic-emulsion-005percent</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026</description>
</item>
<item>
<title>Amneal Receives U.S. FDA Approval for Iohexol Injection</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-approval-for-iohexol-injection</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-approval-for-iohexol-injection</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>First-to-market complex injectable with expected launch in Q1 2026 BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”</description>
</item>
<item>
<title>Amneal Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-reports-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-reports-third-quarter-2025-financial-results</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted</description>
</item>
<item>
<title>Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol</title>
<link>https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-tentative-approval-for-beclomethasone-dipropionate-hfa-inhalation-aerosol</link>
<guid isPermaLink="true">https://6ix.com/company/amneal-pharmaceuticals-inc/news/amneal-receives-us-fda-tentative-approval-for-beclomethasone-dipropionate-hfa-inhalation-aerosol</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment BRIDGEWATER, N.J., Oct. 29,</description>
</item>
</channel>
</rss>